Previous studies reported that HSP90 inhibitors induced sensitivity in crizotinib-resistant NSCLC patients with a secondary ALK mutation, as well as in crizotinib-resistant H2228 cells [22]. The gene discussed is ALK; the disease is non-small cell lung carcinoma.